

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

(Present Status of Competition in the Pharmaceutical Industry)

THURSDAY, NOVEMBER 11, 1976

U.S. SENATE,
SUBCOMMITTEE ON MONOPOLY OF THE
SELECT COMMITTEE ON SMALL BUSINESS,
Washington, D.C.

The subcommittee met, pursuant to recess, at 10 a.m., in room 318, Russell Senate Office Building, Hon. Gaylord Nelson, chairman, presiding.

Present: Senator Nelson.

Also present: Benjamin Gordon, staff economist; and Karen Young, research assistant.

Senator NELSON. The Monopoly Subcommittee of the Senate Small Business Committee will please come to order.

Our first witness this morning is Dr. Everett Ellinwood, associate professor of psychiatry, Duke University Medical Center, Durham, N.C.

We are pleased to have you here this morning.

Your statement will be printed in full in the record.¹

You may present your statement however you desire.

If you would pull the microphone up close, it would help, because the acoustics are very poor in this room.

STATEMENT OF EVERETT H. ELLINWOOD, JR., M.D., PROFESSOR OF PSYCHIATRY, DUKE UNIVERSITY MEDICAL CENTER, DURHAM, N.C.

Dr. ELLINWOOD. Thank you, Mr. Chairman.

I have worked for many years now with most of the central nervous system stimulants, both in a clinical setting as well as in a basic research laboratory.

In considering the anorectic drugs currently in use, it is important to distinguish between the central stimulant effects and anorectic properties.

The amphetamines are perhaps the best prototype of anorectic drugs, having strong central nervous system stimulant activity as well as anorectic properties.

¹ See prepared statement and attachments of Dr. Ellinwood beginning at p. 14668.